Value of positive myocardial technetium-99m-pyrophosphate scintigraphy in the noninvasive diagnosis of cardiac amyloidosis

Wizenberg, Theodore A.; Muz, Jaroslaw; Sohn, Young H.; Samlowski, Wolfram E.; Weissler, Arnold M.

doi:10.1016/0002-8703(82)90331-3

Cited by 120 publications

(43 citation statements)

References 26 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…2A and B). Myocardial technetium-99m pyrophosphate (Tc-99m-PYP) scintigraphy is also valuable (11,12) (Fig. 2C): this isotope may bind to amyloid fibril-associated calcium molecules, producing a positive shadow in amyloid heart.…”

Section: Diagnosis Of Cardiac Amyloidosismentioning

confidence: 99%

Cardiac Amyloidosis: Heterogenous Pathogenic Backgrounds

Ikeda

2004

Intern. Med.

View full text Add to dashboard Cite

Cardiac amyloidosis is a fatal disorder which develops on the basis of the different pathologic conditions in systemic amyloidosis: the most common underlying disease is immunoglobulin light chain-derived primary amyloidosis and the next is transthyretin-related hereditary amyloidosis; the latter disorder, typically represented by familial amyloid polyneuropathy, was long regarded as an endemic disease. However, this disorder has now been shown to involve a highly variable clinical picture due to a large number of transthyretin gene mutations, and many patients with diverse ancestors suffer from severe cardiac amyloidosis. Additionally, senile systemic amyloidosis is now noted as a cause of cardiac dysfunction in elderly individuals. Echocardiogram and myocardial technetium-99m-pyrophosphate scintigraphy can provide characteristic findings. Immunohistochemistry on tissue amyloid, biochemical analysis of serum and urine proteins, and DNA sequencing are usually employed to determine the disease-related amyloid fibril protein.Although systemic amyloidosis has become treatable, the prognosis of each patient who received up-to-date and effective, but nevertheless stressful, therapy depends on the severity of cardiac involvement by amyloid deposition.

show abstract

Section: Diagnosis Of Cardiac Amyloidosismentioning

confidence: 99%

Cardiac Amyloidosis: Heterogenous Pathogenic Backgrounds

Ikeda

2004

Intern. Med.

View full text Add to dashboard Cite

show abstract

“…Various workers have found a positive up take of Tc-99m pyrophosphate in patients with cardiac amyloidosis, especially those with advanced disease [10,[19][20][21], However, others have not found this to be a useful test [22,23]. It is possible that, apart from the severity of amyloid infiltration, the underly ing type of amyloid protein may affect the binding of pyrophosphate in different pa tients.…”

Section: Discussionmentioning

confidence: 99%

Cardiac Amyloidosis Presenting as Ischemic Heart Disease

Narang

Chopra²,

Wasir³

1993

Cardiology

View full text Add to dashboard Cite

show abstract

“…3), fractional shortening of the left ventricle (%FS 35.1%, normal 30-50%) and all Doppler-based indices were within normal limits. On 99m Tcpyrophosphate scintigram no uptake could be detected in the heart (11). Abdominal ultrasonography demonstrated a diffuse increase in echo-brightness of the liver.…”

Section: Case Reportmentioning

confidence: 93%

High-dose Melphalan Followed by Autologous Stem Cell Support in Primary Systemic AL Amyloidosis with Multiple Organ Involvement

et al. 2005

View full text Add to dashboard Cite

A patient with primary systemic AL amyloidosis achieved partial hematological response after 2 courses of VAD (vincristine, doxorubicin and dexamethasone) and subsequent high-dose melphalan followed by autologous peripheral blood stem cell transplantation despite involvement of multiple organs, including the heart. In this patient natriuretic peptides and free light chains in serum were useful as markers of cardiac involvement and therapeutic effects, respectively. When amyloidosisrelated dysfunction is seen in multiple organs, this intensive chemotherapy might be a possible therapeutic option, although several modifications in the regimen and careful management are necessary.

show abstract

Value of positive myocardial technetium-99m-pyrophosphate scintigraphy in the noninvasive diagnosis of cardiac amyloidosis

Cited by 120 publications

References 26 publications

Cardiac Amyloidosis: Heterogenous Pathogenic Backgrounds

Cardiac Amyloidosis: Heterogenous Pathogenic Backgrounds

Cardiac Amyloidosis Presenting as Ischemic Heart Disease

High-dose Melphalan Followed by Autologous Stem Cell Support in Primary Systemic AL Amyloidosis with Multiple Organ Involvement

Contact Info

Product

Resources

About